Related Experiment Video
Updated: May 15, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Hepatitis C treatment - better outcomes through partner support.
Fleur Chapman1, Alexandra McManus
1Curtin Health Innovation Research Institute (CHIRI), Curtin University.
The Australasian Medical Journal
|January 5, 2013
Summary
Supporting partners of hepatitis C patients is crucial. Greater assistance and social support for partners significantly improve treatment outcomes and family relationships during hepatitis C therapy.
Area of Science:
- Hepatology
- Public Health
- Social Sciences
Background:
- Hepatitis C affects 170 million globally, with 3-4 million new infections annually.
- Approximately 1% of Australians have chronic hepatitis C, predominantly men.
- Hepatitis C virus (HCV) infection poses a significant global health burden.
Purpose of the Study:
- To explore the impact of hepatitis C treatment on patients' partners.
- To identify the needs of female partners supporting men undergoing hepatitis C treatment.
- To understand the role of social support in hepatitis C management.
Main Methods:
- Qualitative study using in-depth interviews.
- Recruited 8 partners of male hepatitis C patients and 3 service providers.
- Focused on female partners' experiences during the male patient's treatment phase.
Main Results:
- Partners recognized a need for increased support services.
- Strong social support positively influenced hepatitis C treatment outcomes.
- Social support was vital for maintaining family relationships during treatment.
Conclusions:
- Formal partner support can enhance hepatitis C management.
- Insights gained can improve outcomes beyond medical treatment.
- Addressing partner needs is essential for holistic hepatitis C care.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...